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Abstract: Lysozyme is one of the most important anti-bacterial effectors in the innate immune system
of animals. Besides its direct antibacterial enzymatic activity, lysozyme displays other biological
properties, pointing toward a significant anti-inflammatory effect, many aspects of which are still
elusive. Here we investigate the perturbation of gene expression profiles induced by lysozyme in a
monocyte cell line in vitro considering a perspective as broad as the whole transcriptome profiling.
The results of the RNA-seq experiment show that lysozyme induces transcriptional modulation of the
TNF-α/IL-1β pathway genes in U937 monocytes. The analysis of transcriptomic profiles with IPA®
identified a simple but robust molecular network of genes, in which the regulation trends are fully
consistent with the anti-inflammatory activity of lysozyme. This study provides the first evidence in
support of the anti-inflammatory action of lysozyme on the basis of transcriptomic regulation data
resulting from the broad perspective of a whole-transcriptome profiling. Such important effects can
be achieved with the supplementation of relatively low concentrations of lysozyme, for a short time
of exposure. These new insights allow the potential of lysozyme in pharmacological applications to
be better exploited.
Keywords: lysozyme; inflammation; RNA-sequencing; whole transcriptome profiling; proteome
profiling; TNF-α; IL-1β
1. Introduction
Almost a century after its discovery by sir Alexander Fleming [1], lysozyme is now widely
recognized as one of the most important anti-bacterial effectors in the innate immune system of
animals [2,3], where it plays a key role in response to infection, by digesting peptidoglycan and
destabilizing the cell wall of invading Gram-positive bacteria [4]. Over the years, lysozyme has become
more and more important for studies in the fields of protein chemistry, enzymology, crystallography
and molecular biology [5], and it is widely used as a preservative/maturation inductor in foods and
pharmaceuticals [6–8].
The lysozyme muramidasic enzymatic activity is provided by three different types of evolutionarily
unrelated gene-encoded proteins, named chicken (C)-, goose (G)- and invertebrate (I)-type lysozymes,
which display a broad and partly overlapping taxonomic distribution [5]. Lysozymes are produced by
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a variety of cell types and tissues, and are highly abundant in saliva, mucus and other secretions. The
human protein, encoded by the LYZ gene, pertains to the conventional C-type class and shares high
homology (58% identity) with the chicken lysozyme.
The oral administration of lysozymes is an attractive proposition, as it could help to suppress the
spread of gastrointestinal pathogens, or to modulate the composition of the entire gut microbiota [9,10].
Besides its direct antibacterial enzymatic activity, lysozyme displays other promising biological
properties, which may enable its therapeutic use as an immune-modulating agent in the near future.
For example, lysozyme has remarkable nucleic acid-binding properties, which may explain its antiviral
activity toward HIV-1 [11–13]. Moreover, the ability to stimulate the recovery of lymphocyte CD4+/CD8+
ratio in patients in remission after chemotherapy for malignant diseases [14], and to beneficially act in
the context of human ageing [15], further highlights the multifaceted immune-modulating properties of
this natural product. Lysozyme supplementation can also reduce the concentration of serum advanced
glycation end products (AGEs) and their deposition in the kidneys of early-stage diabetic rats [16,17],
preventing the development of glomerular and renal hypertrophy as well as the overexpression of
AGE receptors (RAGEs) [18].
Recently, a series of immune-histochemical studies have indicated that lysozyme is up-regulated in
the gastrointestinal (GI) tract of patients affected by pathologies characterized by chronic inflammation.
These include Barrett’s oesophagitis, chronic gastritis, gluten-induced atrophic duodenitis (coeliac
disease), collagenous colitis, lymphocytic colitis, ulcerative colitis (UC) and Crohn’s colitis [19–22].
This suggests that this enzyme may be somehow involved in counteracting the development of
the hostile gut microenvironment typical of these pathologies. In support to these observations,
the treatment with exogenous hen egg-white lysozyme (HEWL) can significantly reduce the local
expression of pro-inflammatory cytokines and increase the expression of anti-inflammatory mediators
in a porcine model of colitis, induced by dextran sodium sulphate (DSS), suggesting a role in the
restoration of gut homeostasis [23]. Moreover, the supplementation of exogenous HEWL has a
significant anti-inflammatory effect in subjects affected by inflammatory bowel disease [23].
This behaviour may be also linked to the lipopolysaccharide (LPS)-binding properties of lysozyme,
which have been reported to abrogate TNF-α (tumour necrosis factor alpha) production and to reduce
LPS-related mortality rates in an endotoxin shock murine model [24,25]. Other studies have evidenced
that the anti-inflammatory effect of lysozyme is linked with an inhibition of serum complement
activity [26]. Anti-septic effects have also been reported for PEGylated lysozyme in high mobility
group B1-mediated inflammatory response, both in vitro and in vivo [27]. Moreover, the application
of a charge-engineered lysozyme variant in a murine model of mucoid Pseudomonas aeruginosa lung
infection was able to contrast both the burden of infection and the degree of tissue inflammation [28].
The wide number of biological roles of lysozyme and the significant effects against bacterial and
viral infections, depression of immune response and phlogosis, led to the commercialization and
employment of HEWL in a number of human pathologies, in which its use is consolidated and safe,
since the 1950 (in addition to the indications for which marketing in various countries is authorized, see
also: [29–31]). The therapeutic effectiveness of lysozyme to control the growth of susceptible bacteria is
based on a generally well-known mechanism of action although some aspects, such as the impact of the
peptidoglycan fragments released by the catalytic action, and the muramidase-independent properties,
remain elusive [32,33]. The immune-regulating and anti-inflammatory properties of lysozyme, its
ability to beneficially act in the context of human ageing [15], or to contrast the complications of
chronic diseases like diabetes [16–18], to cite a few, are more recent indications of its importance as
they highlight the potential use of lysozyme as a natural complement to other previously established
pharmacological interventions. How lysozyme work to carry out these corollary activities is much less
known. Regardless of the potential application of lysozyme, a deeper understanding of the cellular and
molecular mechanisms implemented by this molecule is fundamental to improve the appropriateness
of its use.
Int. J. Mol. Sci. 2019, 20, 5502 3 of 23
The interaction of lysozyme with immune system cells is pivotal to all its biological and
pharmacological effects. Although numerous in vitro and in vivo studies have analysed the mechanisms
of action of lysozyme at the molecular level, to the best of our knowledge none has so far considered
a perspective as broad as whole transcriptome profiling. Such an approach would ensure a fuller
overview on the interactions between lysozyme and target cells, allowing the mechanisms of action and
regulatory networks not easily predictable on the basis of current knowledge to be established. With
this study, we aim to fill this gap, investigating the perturbation of gene expression profiles induced by
in vitro lysozyme supplementation in a monocyte cell line, one of the main types of immune cells which
interact with lysozyme. The chosen cellular model is the monocyte U937 cell line, which still expresses
many of the monocytic-like characteristics and is at the same time genetically homogeneous and easily
manageable. In addition, the possibility to differentiate U937 cells to macrophages enables the effects
of lysozyme on two maturation stages of the same cellular lineage to be studied [34]. Through an
in-depth analysis of the genes altered in response to the treatment, we expect to provide a rationale for
an improved understanding of the molecular mechanisms underpinning the diverse pharmacological
activities of lysozyme.
2. Results
The highest number of differentially expressed genes (DEGs) in the U937 monocyte cell line was
detected at the end of the treatment with lysozyme for 1 h (3 up- and 22 down-regulated genes, Table 1).
Table 1. Comparison of the number of genes differentially expressed in U937 cells following
lysozyme treatment.
Duration of Exposure to
Lysozyme (h)
Analysis after the End
of Exposure (h) Up-Regulated Genes Down-Regulated Genes
1 Immediate 3/25 22/25
2 2/25 1/25
24 Immediate 1/25 5/25
Tests of differential expression were performed on the complete human genome (version Hg38), assessing the gene
expression levels of 53,816 annotated features. DEGs were considered significant when p-value ≤ 0.05 and modulus
(fold change) ≥2. The table shows the number of up- or down-regulated genes against the total number of DEGs in
each condition.
The number of DEGs, compared to parallel control samples declined after a further 2 h in a
lysozyme-free culture medium (2 up- and 1 down-regulated genes), and was similar to that observed
in response to the non-stop treatment for 24 h (1 up- and 5 down-regulated genes). Overall lysozyme
affected the expression level of few genes, although some very meaningful fold change values indicated
the possibility of prominent consequences at a functional level. The complete list of DEGs and their
relative fold change values are reported in Table 2.
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Table 2. Differentially expressed genes in U937 cells. Whenever significant, fold change values are shown. Only genes detected as up-or down-regulated in respect of
parallel control samples are shown.
Official Symbol Official Full Name ˆ Compartment ˆ Main Functions ˆ
Fold Change at Different Analysis Time Points
1 h 1 h + 2 24 h
Up-regulated
CCDC73 Coiled-coil domain containing 73 Intracellular (predicted) Unknown - - 7.00
CKMT2 Creatine kinase, mitochondrial 2 Mitochondrial innermembrane Metabolism 20.80 23.25 14.20
SCP2 Sterol carrier protein 2 Peroxisomal matrix Metabolism - - 2.25
TMEM150C Transmembrane protein 150C Plasma membrane Mechanotransduction - 9.20 24.14
TTI2 TELO2 interacting protein 2 Cytosol DNA damage response 3.86 - -
WDR47 WD repeat domain 47 Intracellular Development biology - - 2.56
Down-regulated
ADM Adrenomedullin Extracellular region Signal transduction −24.14 - -
CCL1 C-C motif chemokine ligand 1 Extracellular region Signal transduction −13.91 - -
CCL3 C-C motif chemokine ligand 3 Extracellular region Immune system −17.61 - -
CCL3L3 C-C motif chemokine ligand 3 like 3 Extracellular region Immune system −12.98 - -
CCL7 C-C motif chemokine ligand 7 Extracellular region Immune system −12.95 - -
DLG2 Discs large MAGUK scaffold protein 2 Cytosol Neuronal system −110.73 −13.15 −8.48
FTH1 Ferritin heavy chain 1 Extracellular region;Cytosol
Immune system;
Vesicle-mediated transport;
Transport of small molecules
−2.28 - -
GDF15 Growth differentiation factor 15 Extracellular region −11.97 - -
IER3 Immediate early response 3 Cytosol Signal transduction −2.82 - -
IFI6 Interferon alpha inducible protein 6 Plasma membrane Immune system −5.40 - -
IL1B Interleukin 1 beta Extracellular region;Cytosol Immune system −7.99 - -
IL1RN Interleukin 1 receptor antagonist Plasma membrane Immune system −6.06 - -
INHBA Inhibin beta A subunit Extracellular region Metabolism of proteins;Signal transduction −12.72 - -
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Table 2. Cont.
Official Symbol Official Full Name ˆ Compartment ˆ Main Functions ˆ
Fold Change at Different Analysis Time Points
1 h 1 h + 2 24 h
ISG15 ISG15 ubiquitin-like modifier Cytosol;Nucleoplasm
Disease;
Immune system;
DNA repair
−3.73 - -
MMP1 Matrix metallopeptidase 1 Extracellular region
Extracellular matrix organisation;
Haemostasis;
Metabolism of proteins;
Immune system
−4.63 - -
MMP9 Matrix metallopeptidase 9 Extracellular region
Development biology;
Extracellular matrix organisation;
Immune system;
Signal transduction
−7.52 - -
MTRNR2L2 MT-RNR2 like 2 Extracellular region Programmed cell death −2.14 - -
PLAUR Plasminogen activator, urokinasereceptor
Plasma membrane;
Endoplasmic reticulum
membrane;
Specific granule membrane;
Endoplasmic reticulum
lumen
Immune system;
Metabolism of proteins −2.55 - -
RGS16 Regulator of G protein signalling 16 Plasma membrane Signal transduction −2.69 - -
SPP1 Secreted phosphoprotein 1
Extracellular region;
Endoplasmic reticulum
lumen
Extracellular matrix organisation;
Gene expression;
Signal transduction
−16.71 - -
TIMP1 TIMP metallopeptidase inhibitor 1
Extracellular region;
Platelet alpha granule
lumen;
Endoplasmic reticulum
lumen
Extracellular matrix organisation;
Haemostasis;
Immune system;
Metabolism of proteins
−2.93 - -
TJP1 Tight junction protein 1
Cell junctions;
Plasma membrane;
Cytosol;
Golgi-associated vesicle
membrane
Gene expression (transcription);
Programmed cell death;
Vesicle-mediated transport;
Signal transduction
2.14 - -
VIM Vimentin Cytosol
Immune system;
Muscle contraction;
Programmed cell death
−3.88 - -
ˆ www.genenames.org; www.genecards.org; www.reactome.org; www.uniprot.org; www.proteinatlas.org.
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Overall, the functions of most of the DEGs detected at the end of the exposure to lysozyme for 1 h
were linked with immune system activity (26.5%), signal transduction (16.3%), metabolism (12.2%) and
extracellular matrix organisation (8.2%) (Figure S1, Supplementary Material). At this time point, the
majority of DEGs (88%) were down-regulated (Figure 1a; Figures S2 and S3, Supplementary Material).
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b), or treated for 24 h and analysed immediately at the end of the treatment (24 h, c). Fold change 
values  in  respect  of  parallel  control  samples  are  shown  in  ascending  order.  Complete  gene 
expression data is available in Supplementary Table S1. 
Many genes showed, compared  to control samples, relevant  fold change values  that were  in 
turn no  longer detectable  in  cells kept  for  an  additional  2 h  in  a  lysozyme‐free  culture medium 
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Figure 1. Differentially expressed genes in U937 cells treated with lysozyme 15 µg/ L for 1 h and
analysed i ediately at the end of the treatment (1 h, a) or 2 h after the end of the treatment (1 h +
2, b), or treated for 24 h and analysed i mediately at the end of the treatment (24 h, c). Fold change
values in respect of parallel control samples are shown in ascending order. Complete gene expression
data is available in Supplementary Table S1.
, are t tr l l s, r l t f l l s t t r
t l i ll t i l -
t t ri l), r i ll j t t - t
t i ; , i ti i t
f t e alterations observed. The only genes that maintained a significant v r ati n of expression at
all times of investigation were DLG2 (Di cs Large MAGUK Scaffold Protein 2) and CK T2 ( ti
i , it c rial 2), ic r i e - -r late , r s ectively,
of the alteration f DLG2 decreased ov r time (Figur 2). Another relevant DEG, TMEM150C
(Transmembrane Protein 150C), showed a delayed over-expression, undetectable at the firs time point
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of analysis, but highly significant in the later ones, regardless of the presence of lysozyme in the cell
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I e it l sis (IPA®) was then used to investigate he possible mode of action and
physiological effects of lys zyme treatment in U937 cells, focu ing in particular on the analysis of DEGs
detected at 1 h, since this was the experimental time point d splaying the most relevant alterations of
gene expression profiles.
he pathway analysis showed sign ficant alterations of canonical pathways th t are in olved
in adhesion and diapedesis of granulocytes and agranulocytes (Figure 3 ). The analysis of
upstream regulators, which may possibly underpin the observed alt rations, identified a strong
correlation betwee the transcriptional profiles and the nhibiti n of NF-κB (nuclear factor
ka -li - - of activated B cells), TNF-α (tumour necrosis fact r alpha), IFNG (interferon
gamma), IL-1 (interleukin 1) and also of other genes inv lved in the regulati n of inflammatory processes
(Figure 3b), suggesting that the anti-inflammatory effect ex rted by lysozyme might be mediated by
these proteins. Th most likely affect d downstream biol gical pathways were predicted to act in n
inhibitory manner in th immune cell trafficking and inflammatory respons . Conversely, a single
process, i.e., cell death, was pr dicted to be slightly up-regulated (not shown). It s imp rtant to note
that, based on the list of DEGs, no significant t xic effect was predicted by IPA® neither at the level of
th whole o ganism nor of a sp cific tissue.
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CKMT2  and DLG2 were  placed  in  peripheral  regions,  suggesting  that  these  two  genes  have  a 
marginal  role  in  the  direct  response  to  lysozyme.  However,  their  marked  and  long‐lasting 
Figure 3. Top ten canonical pathways (a) and top ten up-stream regulators (b) detected as altered by
IPA® analysis. In (a) the ‘ratio’ value is the ratio between altered genes and total genes in the pathway,
and in (b) bars represent the pathway z-score, the red line indicates the p-value of the prediction.
In order to explore in greater detail the possible physiological effects of lysozyme treatment, a
custom gene regulatory network was built using CKMT2 and DLG2 as probes, i.e., the two genes
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displaying the most significant and long-lasting alterations. The two genes were used to search, within
the ingenuity knowledge base, any possible connecting path to the other detected DEGs.
The resulting gene regulatory network clearly showed a central role for TNF-α and IL-1, while
CKMT2 and DLG2 were placed in peripheral regions, suggesting that these two genes have a marginal
role in the direct response to lysozyme. However, their marked and long-lasting differential expression
indicates that these two genes may be used as potential molecular markers to track the effect of
lysozyme treatment, at least within the first 24 h (Figure 4).
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It is worth noting that TNF‐α was not found among the significantly down‐regulated DEGs in 
the RNA‐seq experiment, even though IPA predicted its inhibition with high confidence because 
of  the observed down‐regulation of several genes under direct positive  transcriptional control by 
TNF‐α  itself.  However,  while  the  levels  of  TNF‐α  mRNA  remained  steady  throughout  the 
experimental timeline, the inhibition of TNF‐α activity could possibly occur at the protein level (e.g., 
by  increased protein  turnover or by post‐translational modifications). Moreover, TNF‐α may be a 
highly responsive gene, whose expression levels vary very rapidly in response to the treatment with 
lysozyme, vanishing within a  few minutes after  the  treatment and becoming undetectable at  the 
time of analysis. In contrast to TNF‐α, whose levels do not vary, IL‐1β (interleukin 1 beta) displays a 
strong transcriptional repression with a −7.99‐fold change value at 1 h in comparison to untreated 
cells (Figure 1a and Table 2). 
LC‐MS/MS  (liquid  chromatography‐tandem  mass  spectrometry)  analysis  identified  and 
quantified  proteins  in U937  cells,  collected  24  h  after  exposure  to  lysozyme  15  μg/mL  for  1  h 
(hereafter referred  to as 1 h + 24) or  for consecutive 24 h  (hereafter referred  to as 24 h + 24). The 
differences of protein abundance comparing the two conditions and of their statistical significance 
are  shown by volcano plots  constructed by plotting  the Log2  ratio on  x‐axis  for  each quantified 
protein and the significance of the calculated difference as ‘−log10(p‐value)’ on y‐axis. Dashed lines 
mark different thresholds of statistical significance of the difference. Protein spots represented above 
the dashed lines show a significant difference in the two samples. 
Figure 4. IPA® analysi of signalling pathways of the genes differ ntially expressed upon lysozyme
treatment. U937 cells wer treated with lysozyme 15 µg/mL for 1 h and alysed immediat ly t the end
of the treatment (1 h). Down-regulated genes by lysozyme treatment are mark d in green, up-regulat d
genes are marked in red, orange colour indicates the predic ion of an activati n, blue colour the
prediction of an inhibiti n; continuous line indicates direct rel ionships, dashed line in icates a
indirect rel tio ship (on or more intermediates), yellow colour indicates re ationsh ps non-consistent
with the state of the down- ream molecule, grey colour indicates an unpredicted effect.
It is worth noting that TNF-α was not found among the significantly down-regulated DEGs in the
RNA-seq experiment, even though IPA® predicte its inhibition with high confidence because of the
obs rved down-regulatio of s veral genes under direct positive transcriptional contr l by TNF-α itself.
However, whil the levels of TNF-α mRNA remained stea y throughout the experimental timeli e, the
inhibition of TNF-α activity could possibly occur at the protein level ( .g., by increased protein turnover
or by post-tr nslatio al modifications). Moreover, TNF-α may be a highly esponsive gene, whose
expression l vels vary very rapidly in response to the tre tment with lysozyme, vanishing within a few
minutes after the treatment and becoming und tect ble at the time of analysis. In contrast to TNF-α,
whose lev ls do not vary, IL-1β (interleukin 1 beta) displays a strong transcriptional repression with a
−7.99-fold change value at 1 h in comparison to untreated cells (Figure 1a and Table 2).
LC-MS/MS (liquid chromatography-tandem mass spectrometry) analysis identified a d q antified
proteins in U937 cells, co lected 24 h after exposure to lysozyme 15 µg/mL for 1 h (hereafter referred
to as 1 h + 24) or for consecutive 24 h (hereafter r ferred to as 24 h + 24). The differences of protei
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abundance comparing the two conditions and of their statistical significance are shown by volcano
plots constructed by plotting the Log2 ratio on x-axis for each quantified protein and the significance
of the calculated difference as ‘−log10(p-value)’ on y-axis. Dashed lines mark different thresholds
of statistical significance of the difference. Protein spots represented above the dashed lines show a
significant difference in the two samples.
No significant differences were observed between the lysozyme-treated and the relevant controls in
both experimental conditions of treatment (1 h + 24 or 24 h + 24) (Figures S8 and S9 in the Supplementary
Material). Conversely, significant different protein levels were observed when comparing the two
experimental schemes in the controls (Table 3 and Figure 5a) or in the treated cells (Table 4 and
Figure 5b), probably because of the different growth time of the cells in the two experimental settings.
Table 3 compares control 24 h + 24 versus control 1 h + 24; 8 proteins are significantly down-regulated
and 15 proteins are significantly up-regulated. A similar finding characterizes the comparison between
lysozyme 24 h + 24 versus lysozyme 1 h + 24 (Table 4), where the proteins down- and up-regulated
are 9 and 16, respectively. Most of the proteins differentially expressed are common to control and
lysozyme-treated cells and are marked with S (=shared) in Tables 3 and 4. That is likely a result related
to the time chosen for the samples collection after the end of treatment, more than an effect of the
treatment itself. The comparison of the results of the proteomic and the RNA-seq analyses highlighted
a good correlation between the expression of mRNAs and the detected abundance of encoded proteins
both in controls (Figure 6a) and in lysozyme-treated U937 cells (Figure 6b). The vast majority of down-
or up-regulated proteins showed an identical trend of expression at the mRNA level, even though the
fold change values observed in RNA-seq experiments were often more pronounced than their detected
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Figure 5. LC-MS/MS (liquid chromatography-tandem ass spectrometry) analysis, volcano plots show
the differences of protein abundance comparing the control cells at 24 h + 24 vs. 1 h + 24 (a), and
lysozy e-treate cells at 24 h 24 vs. 1 h 24 (b). ashe lines ark the threshol of statistical
si ifica ce it 0.05.
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Table 3. LC-MS/MS identification results of differentially expressed protein spots in U937 control cells upon the two experimental schemes (Ctrl 24 h + 24 versus Ctrl 1
h + 24).
Protein Name Gene Name Accession No. ˆ Intensity Mean Difference −log10(p-Value) Subcellular Location ˆ #
Cytochrome P450 CYP1A1 E7EMT5 −3.814 1.977 ER S
Dipeptidase 1 DPEP1 P16444 −3.595 3.086 PM S
Integrin alpha-M ITGAM P11215 −3.111 4.298 PM, OL S
Carbohydrate sulfotransferase 14 CHST14 Q8NCH0 −2.780 2.386 GA -
Protein S100-A8 S100A8 P05109 −2.607 3.267 PM, ExR/S, Cy, OL S
Protein S100-A9 S100A9 P06702 −2.481 4.341 PM, ExR/S, Cy S
Gamma-interferon-inducible lysosomal thiol reductase IFI30 P13284 −1.971 3.228 ExR/S, OL -
SAM domain-containing protein SAMSN-1 SAMSN1 Q9NSI8 −1.778 4.143 N -
Glycerol-3-phosphate dehydrogenase, mitochondrial GPD2 P43304 1.835 3.529 M S
Calcium/calmodulin-dependent protein kinase type 1 CAMK1 Q14012 2.088 3.662 N, OL S
Cathepsin G CTSG P08311 2.103 3.661 OL (cell surface) S
Aflatoxin B1 aldehyde reductase member 3 AKR7A3 O95154 2.203 3.480 OL (cytoplasm) S
Long-chain-fatty-acid—CoA ligase 5 ACSL5 Q9ULC5 2.327 5.667 ER, M S
HLA class II histocompatibility antigen, DRB1-15 beta chain HLA-DRB1 P01911 3.731 2.377 PM, E, L, GA, ER S
HLA class II histocompatibility antigen, DRB1-14 beta chain HLA-DRB1 Q9GIY3 3.851 3.219 PM, E, L, GA, ER -
HLA class II histocompatibility antigen, DRB1-9 beta chain HLA-DRB1 Q9TQE0 4.216 3.003 PM, E, L, GA, ER S
HLA class II histocompatibility antigen, gamma chain CD74 P04233 4.338 3.349 PM, GA, E, L, ER -
Nicotinate-nucleotide pyrophosphorylase [carboxylating] QPRT Q15274 4.405 3.701 C, ExR/S, OL S
Neutrophil elastase ELANE P08246 5.024 3.358 ExR/S, L, OL S
HLA class II histocompatibility antigen, DR beta 5 chain HLA-DRB5 Q30154 5.123 3.312 PM, E, L, GA, ER S
HLA class II histocompatibility antigen, DRB1-16 beta chain HLA-DRB1 Q29974 6.902 3.752 PM, E, L, GA, ER S
Kinesin-like protein KIF3B KIF3B O15066 7.129 3.922 Cy, OL -
HLA class II histocompatibility antigen, DR alpha chain HLA-DRA A0A0G2JMH6 7.236 5.473 PM, OL S
ˆ Source: www.uniprot.org; C = cytosol, Cy = cytoskeleton, E = endosome, ER = endoplasmic reticulum, ExR/S = extracellular region or secreted, GA = Golgi apparatus, L = lysosome,
M = mitochondrion, N = nucleus, OL = other locations, PM = plasma membrane. #: S (shared) indicated proteins differentially expressed both in controls and in lysozyme-treated U937
cells (see for comparison Table 4).
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Table 4. LC-MS/MS identification results of differentially expressed protein spots in U937 lysozyme-treated cells upon the two experimental schemes (LYS 24 h+24
versus LYS 1 h+24).
Protein Name Gene Name Accession No. ˆ Intensity Mean Difference −log10(p-Value) Subcellular Location ˆ #
Dipeptidase 1 DPEP1 P16444 −3.010 4.354 PM S
Dehydrogenase/reductase SDR family member 9 DHRS9 Q9BPW9 −2.967 3.462 ER -
Integrin alpha-M ITGAM P11215 −2.872 3.416 PM, OL S
Protein S100-A8 S100A8 P05109 −2.784 3.495 PM, ExR/S, Cy, OL S
Glycerol-3-phosphate acyltransferase 3 GPAT3 Q53EU6 −2.564 3.446 ER -
Protein S100-A9 S100A9 P06702 −2.506 3.373 PM, ExR/S, Cy, OL S
Immunoglobulin alpha Fc receptor FCAR P24071 −2.314 3.301 PM, ExR/S -
Cytochrome P450 CYP1A1 E7EMT5 −2.307 3.075 ER S
Creatine kinase U-type, mitochondrial CKMT1A P12532 −2.129 3.430 M -
Protein DPCD DPCD Q9BVM2 1.884 4.083 N -
Aflatoxin B1 aldehyde reductase member 3 AKR7A3 O95154 1.906 3.661 OL (cytoplasm) S
Cathepsin G CTSG P08311 2.084 4.115 OL (cell surface) S
Sulfotransferase 1A4 SULT1A4 P0DMN0 2.118 4.406 OL (cytoplasm) -
Glycerol-3-phosphate dehydrogenase, mitochondrial GPD2 P43304 2.154 3.692 M S
Long-chain-fatty-acid- -CoA ligase 5 ACSL5 Q9ULC5 2.193 3.405 ER, M S
Calcium/calmodulin-dependent protein kinase type 1 CAMK1 Q14012 2.292 4.360 N, OL S
Azurocidin AZU1 P20160 2.332 3.876 OL (cytoplasmicgranule membrane) -
Interferon regulatory factor 8 IRF8 Q02556 2.980 2.604 N, OL -
Nicotinate-nucleotide pyrophosphorylase [carboxylating] QPRT Q15274 3.881 2.424 C, ExR/S, OL S
HLA class II histocompatibility antigen, DRB1-15 beta chain HLA-DRB1 P01911 3.917 2.424 PM, E, L, GA, ER S
HLA class II histocompatibility antigen, DRB1-9 beta chain HLA-DRB1 Q9TQE0 4.142 3.599 PM, E, L, GA, ER S
HLA class II histocompatibility antigen, DR beta 5 chain HLA-DRB5 Q30154 4.556 2.820 PM, E, L, GA, ER S
Neutrophil elastase ELANE P08246 6.238 4.969 ExR/S, L, OL S
HLA class II histocompatibility antigen, DRB1-16 beta chain HLA-DRB1 Q29974 6.658 4.247 PM, E, L, GA, ER S
HLA class II histocompatibility antigen, DR alpha chain HLA-DRA A0A0G2JMH6 7.888 5.519 PM, OL S
ˆ Source: www.uniprot.org; C = cytosol, Cy = cytoskeleton, E = endosome, ER = endoplasmic reticulum, ExR/S = extracellular region or secreted, GA = Golgi apparatus, L = lysosome,
M = mitochondrion, N = nucleus, OL = other locations, PM = plasma membrane. #: S (shared) indicated proteins differentially expressed both in controls and in lysozyme-treated U937
cells (see for comparison Table 3).
Int. J. Mol. Sci. 2019, 20, 5502 13 of 23
 
Int. J. Mol. Sci. 2019, 20, x; doi: FOR PEER REVIEW  www.mdpi.com/journal/ijms 
 
(a) 
 
(b) 
Figure 6. Correlation between the differential expression of proteins and of mRNAs in the control 24 
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Figure 6. Correlation between the differential expression of proteins and of mRNAs in the control 24 h
+ 24 versus control 1 h + 24 (a) and in LYS 24 h + 24 versus LYS 1 h + 24 (b) in U937 cells.
3. Discu sion
l st ft r its discovery, lysozyme still attracts considerable interest, and remains the
subject of many research projects. Because of the well-established role of lysozyme in anti-bacter al
defence, it has become a p radigm for the functioning of the innate immune system. Neverthele s, the
precise contribution of lys zyme to antibacterial defence in different tissu s is still lacking and many
spects concer ing its non-catalytic biological role are n t completely understood. An interesting
development concerns the possibility to attribute to lysozyme additional functions, besides antibacterial
defence, such as a potent a ti-inflammatory activity [29,35,36]. Lysozyme significantly suppresses the
produ tion of the inflammatory cytokines TNF-α, IL-1β and IL-6 (Interleukin 6) [37–39], independently
from muramidasic activity, b cause of the peptide motifs found in the N-terminal region of the
protein [40]. Fur hermore, Gallo et al. [41] showed that lysozyme is able to prevent the production
and release of inflammatory mediators, such as IL-6, and to reduce macrophage recruitment in the
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inflammatory site induced by AGE (advanced glycation endproducts) in HK-2 proximal tubular
epithelial cells. However, the detailed mechanism of this action and the exact molecular basis
underpinning this behaviour are still undefined.
To gain an improved molecular basis for the many activities of this multi-tasking protein, we
decided to investigate the transcriptional effects of the supplementation of very low concentrations
of HEWL (15 µg/mL ≈ 1 µM) on a monocyte cell line. Our approach takes advantage of the
exploratory capacity of whole RNA-sequencing analysis, integrating transcriptome analysis with
proteome profiling, and allowing a comprehensive overview of the molecular alterations occurring in
this experimental system.
The results of the RNA-seq analysis showed a limited effect on gene expression, with a small
number of DEGs detected at all time points, which generally displayed modest fold change values.
The only exceptions were the DLG2 and CKMT2 genes, which were differentially expressed in all
the experimental conditions tested and displayed a particularly high fold change value in U937
cells collected immediately after the end of exposure to lysozyme (1 h). DLG2 (discs large MAGUK
scaffold protein 2), encoding a member of the MAGUK family of membrane-associated guanylate
kinases with a role in protein–protein interactions at synapses and in tight junctions pathways was
significantly down-regulated in response to HEWL treatment. By contrast, CKMT2, encoding a
mitochondrial creatine kinase responsible for the high-energy phosphate transfer from mitochondria to
the cytosol carrier creatine, was significantly over-expressed. The significant changes of the expression
of these two genes do not permit, by themselves, to establish a functional hypothesis on the biological
activity of lysozyme on monocyte cells. We opted for an in-depth analysis of the set of DEGs and of
their modulation at 1-h exposure to lysozyme, which allowed us to formulate biological hypotheses
consistent with the strong modulation of DLG2 and CKMT2. Indeed, at this time point, a number of
DEGs were significantly altered in addition to DLG2 and CKMT2, but these transient regulatory effects
were practically eliminated after 2 and 24 h.
Data from the literature show that significant alterations of TNF-α and IL-6 gene expression can
be detected by RT-PCR after treatment with lysozyme in LPS-activated peritoneal macrophages at 500
µg/mL (approximately 35µM) [38]. The effective anti-inflammatory concentrations of lysozyme-derived
peptides are in the range 25–50 µM, a concentration in line with the levels of lysozyme in breast
milk [40]. Therefore, the limited intensity and the low persistence of the effects on the transcriptome of
the treated cells might depend on the much lower concentration of lysozyme used in this study (1
µM). We may hypothesize that the transcriptional and proteomic alterations detected may involve a
greater number of genes, persist for a longer time span or affect with higher intensity cells exposed to
higher HEWL doses. However, the present study highlights that a concentration as low as 1 µM can
already exert a transient response in treated cells, suggesting a wide spectrum of active doses for this
natural product.
The DEGs were then subjected to IPA® to build a regulatory network based on the literature
data contained in the IPA® Knowledge Base. The highly significant findings that emerged from
the comparison between treated and untreated U937 cells after 1 h, revealed a series of canonical
pathways whose activity was predicted as ‘altered’. From these, some showed a clear directionality,
while others were discarded because they were not relevant for the biological context examined
in this study. The regulatory network built with the IPA® was based on CKMT2 and DLG2 as
hinge points because of their extremely significant fold change values and the persistence of their
alteration at 1 h and up to 24 h. The RNA-seq results show that MMP-9 (matrix metallopeptidase
9), CCL1 (chemokine ligand 1), IL-1B, and IL-1 genes, belonging to the regulation networks of DLG2
and CKMT2, were also down-regulated at 1 h, suggesting a very rapid onset of the cell response to
lysozyme. IL-1 and IL-1B, among the up-stream regulators predicted to be most likely involved in
response to lysozyme form a central node in the network because of their connections with several
other differentially expressed genes. Despite its prediction as a key repressed upstream regulator in
lysozyme response, the TNF-α gene was not differentially expressed at the transcriptional level. The
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important role of TNF-α at the crossroads of regulation of a number of the other DEGs detected in
this study is strongly supported by the high number of relationships in the IPA® regulatory network
(Figure 4). Moreover, literature data have previously demonstrated that lysozyme can strongly inhibit
the transcription of TNF-α and IL-1β [24,25,42]. It is noteworthy that many of the down-regulated genes
under the transcriptional control of TNF-α are involved in inflammatory processes. CCL3 (chemokine
ligand 3), known also as macrophage inflammatory protein 1-alpha, is a cytokine that activates
polymorphonucleate leucocytes, which is also involved in the acute phase of inflammation [43]. CCL7
(chemokine ligand 7) is a chemokine that regulates macrophage function [44]. CCL3L3 (chemokine
ligand 3-like 3), a cytokine with high similarity to CCL3 is implicated in the regulation of immune cell
functions and is up-regulated during an inflammatory response [45,46]. Immediate early response
3 (IER3) acts in the immediate response mechanism and protects cells from Fas and TNF-α-induced
apoptosis [47]. ISG15 (interferon-stimulated gene 15) is a ubiquitin-like protein with chemotactic
function that recruits neutrophils in the sites of inflammation [48]. Regarding the lack of regulation of
the TNF-α gene, it is essential to stress that RNA-seq data can only provide indications on the biological
layer related to transcription. However, another order of dynamicity is added by post-transcriptional
and post-translational regulation of gene expression. Several other factors like the regulation of
translation, protein turnover and the regulation of its activity by post-translational modifications,
including the interaction with co-factors, can together modulate the biological activity of a protein
without the appreciable involvement of modifications at the mRNA level. Furthermore, a very recent
study conducted in mice with LPS-induced systemic inflammation reports the significant suppression
of TNF-α protein levels in serum and spleen after oral administration of lysozyme but, in contrast
TNF-α gene expression resulted correspondingly not affected [39].
Overall, the analysis of the RNA-seq data suggests that, independently of the rapid onset and
fading of the anti-inflammatory activity exerted by lysozyme, HEWL treatment results in a long-lasting
alteration of the DLG2 and CKMT2 genes, which could be considered as molecular signature of the
lysozyme activity that takes place. Further support of this hypothesis is given by the analysis of
the effects of lysozyme on U937 cells differentiated to macrophages. Indeed, the whole RNA-seq
experiment was specifically designed considering both monocytes and macrophages as cellular models,
in order to investigate the effects of lysozyme on two maturation stages of the same cellular lineage.
Accordingly, the experiments were conducted both with U937 monocytes as such, and after their
differentiation into macrophages upon treatment with PMA (phorbol-12-myristate-13-acetate) 50 ng/mL
for 72 h before the exposure to lysozyme. Surprisingly, lysozyme induced in macrophages results in
the transcriptional modulation of very few genes (data not shown). It is, however, remarkable that
these differentially expressed genes also included the very same genes that were also differentially
expressed, at all time points, in monocytes, i.e., DLG2 and CKMT2.
The functional hypotheses and the molecular networks highlighted in the present study are in
good agreement with the results of a recent paper [38], which reports a study carried out with mouse
macrophages stimulated with LPS to induce an inflammatory state. In that experimental model,
lysozyme acted as a potent inhibitor of IL-6 and TNF-α in a dose-dependent manner, both at the protein
and at the mRNA levels. At the level of the molecular pathway, lysozyme seems to act by reducing the
phosphorylation of JNK (c-Jun N-terminal kinase), a member of the MAPK (mitogen activated protein
kinase) family, which is also involved in the cell inflammatory response [49]. Indeed, phosphorylation
of JNK induces the expression of many inflammatory cytokines, including TNF-α itself [50]. Moreover,
the study of Tagashira and co-workers, similar to ours, did not reveal any toxic effect of lysozyme for
the treated cells, further confirming the reliability of our observations and predictions.
In our attempts to understand the effects of lysozyme on U937 cells, by integrating
transcriptomic and proteomic data, we were unable to detect any significantly differentially expressed
protein in lysozyme-treated compared to untreated cells. Overall, literature on the integrative
transcriptomic-proteomic analyses revealed only a poor correlation between the quantities of mRNAs
and the corresponding proteins [51,52], which is indicative of a complex regulatory mechanism,
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controlling the expression mechanism at both the RNA and protein levels, and involves multiple layers
of gene regulation like genomic variations and gene expression. Another order of dynamicity is added
by post-transcriptional and post-translational regulations of gene expression. These include, but are not
limited to, alternative splicing [53] and editing of expressed transcripts and post-translational addition
of covalent modifications to proteins. Thus, several isoforms or proteoforms, with distinct structural
and functional attributes, may originate from a given gene. The biological uncoupling between the
levels of mRNA and proteins may be the consequence of half-life difference between proteins and
mRNAs, these latter being five-times less stable than proteins in mammalian cells [54]. Furthermore,
ubiquitination, phosphorylation and cellular localization are some of the post-translational regulations
that can affect the protein half-lives and thus, their detection [51]. Studies have reported that mRNA
abundance can predict protein abundance only partially, i.e., for approximately 40% of genes [52,55].
Also, proteomics lacks the sensitivity to detect poorly abundant proteins and it is limited in its
ability to identify novel proteoforms resulting from alternative splicing or SNPs (single nucleotide
polymorphisms). The fractionation approach used in this proteomic study, although not having
the ability of other techniques, such as targeted proteomics [56], to detect the expression level of
low abundance proteins, allowed us to provide the relative quantification of more than 6100 protein
groups and to obtain a general overview on the translational molecular layer. Our study shows
differentially expressed protein levels in samples collected at 24 h + 24 vs. 1 h + 24 in both controls and
lysozyme-treated cells. This seems to be related to the growth time features of the cells being used,
rather than to the pharmacological treatment. The differentially expressed protein levels follow the
same trend of their relevant mRNAs (Figure 6a,b), albeit with minor shifts in expression, confirming
the greater sensitivity of the RNA-seq analysis over the analysis of proteomic data.
4. Materials and Methods
4.1. Materials
All materials were purchased from Sigma-Aldrich (St. Louis, MO, USA), unless otherwise
indicated. HEWL was purchased from Fluka (Honeywell Fluka™, Charlotte, NC, USA).
4.2. Cell Line and Treatment
The U937 cell line is a human immortalized monocyte cell line, originally obtained from pleural
diffusions of a patient affected by histiocytic lymphoma [34]. It was kindly supplied by Dr. S. Pacor
(Dept. of Life Sciences, University of Trieste) and maintained in RPMI-1640 supplemented with
10% foetal bovine serum (FBS, Gibco, Invitrogen™, Grand Island, NY, USA), 2 mM l-glutamine
(EuroClone™, Devon, UK), 100 IU/mL penicillin and 100 µg/mL streptomycin (EuroClone™). Cells
were kept in an incubator with 5% CO2 and 100% relative humidity at 37 ◦C. Cells were grown in
suspension in 25 cm2 flasks; cell viability was checked by the trypan blue dye exclusion test.
For experimental purposes 3 × 106 cells were sown in T25 flasks in 9 mL of their complete culture
medium and let grow 72 h before pharmacological treatment. The exposure to lysozyme 15 µg/mL
was carried out by adding to each flask 1 mL of complete culture medium containing 150 µg/mL of
lysozyme (treated cells) or 1 mL of complete culture medium (controls). The treatment was conducted
according to two experimental schemes: (i) In the first one, the cells were exposed to lysozyme for 1 h
at 37 ◦C, 5% CO2 and 100% relative humidity. The samples to be processed by RNA-sequencing were
prepared immediately at the end of the treatment (hereafter referred to as 1h), and at 2 h after the end
of treatment (hereafter referred to as 1 h + 2); in the latter case cells were left in fresh complete culture
medium for an additional 2 h time in an incubator at 37 ◦C, 5% CO2, and 100% relative humidity
after the removal of the lysozyme treatment solution by centrifugation for 7 min (300× g) at 4 ◦C. A
supplementary time point analysis at 24 h after the end of treatment was employed for proteomic
analysis only. In this case, cells were left in fresh complete culture medium for further 24 h in an
incubator before collection (hereafter referred to as 1 h + 24) after the removal of the lysozyme treatment
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solution by centrifugation for 7 min (300× g) at 4 ◦C; (ii) in the second experimental scheme, the cells
were exposed to lysozyme for 24 h nonstop and processed for RNA-sequencing immediately at the
end of the treatment (hereafter referred to as 24 h); the proteomic analysis was conducted after further
24 h in fresh complete medium after the removal of the lysozyme treatment solution by centrifugation
at the conditions indicated above (hereafter referred to as 24 h + 24). Each experimental condition
corresponds to a biological triplicate.
4.3. Whole Transcriptome Expression Profiling via RNA-seq
At the end of each experimental treatment the cells were collected and centrifuged for 7 min
(300× g) at 4 ◦C, the supernatant was discarded and the cell pellet transferred in an Eppendorf tube,
washed with 1 mL of cold PBS (phosphate buffered saline) and centrifuged again for 7 min (800× g)
at 4 ◦C. The supernatant was then discarded and the cell pellet re-suspended in an appropriate
volume of the lysis buffer of the extraction kit. Total RNA was isolated using the Agilent Absolutely
RNA Miniprep Kit (Agilent Technologies, Santa Clara, CA, USA) according to the manufacturer’s
protocol. The RNA concentration and purity were calculated using spectrophotometer measurements
(evaluating the ratio of absorbance at 260 and 280 nm as a measure of protein contamination, and the
ratio of absorbance at 260 and 230 nm as a measure of carbohydrate contamination). RNA integrity
was examined by capillary electrophoresis (BioAnalyzer 2100, Agilent Technologies) to ensure the
achievements of a RNA integrity number (28S to 18S ribosomal RNA) >9, required for the preparation
of the libraries for RNA-sequencing.
4.4. Library Preparation and RNA-Sequencing
Barcoded sequencing libraries for all samples selected for RNA-sequencing were prepared using
QuantSeq 3′ mRNA-Seq Library prep kit produced by Lexogen (Wien, Austria), according to the
manufacturer’s instructions. Briefly, this strategy generates sequencing libraries enriched in regions
close to the 3′ end of polyadenylated RNAs, to enable cost-saving multiplexing with reduced sequencing
depth compared to conventional RNA-seq protocols, while maintaining the possibility to accurately
calculate gene expression levels with no need of a normalization step based on transcript length.
Following quality evaluation with an Agilent Bioanalyzer instrument, the libraries obtained were
opportunely pooled in equimolar concentrations and sent to the sequencing centre at the Genomics
Core of the Oklahoma Medical Research Foundation, where they were sequenced on a single lane of
an Illumina NextSeq 500 platform, run in High Output mode with a single-end 75 base pair strategy.
Raw sequence data have been deposited in the NCBI SRA database under the accession ID SRP124220,
linked to BioProject PRJNA417221.
4.5. Sequencing Data Analysis
Raw demultiplexed sequencing data were provided from the sequencing centre and
imported in the CLC Genomics Workbench 10 (Qiagen, Hilden, Germany) environment,
where the trimming procedure was carried out using the following parameters: first,
reads were trimmed by quality, setting the quality score threshold to 0.05 and removing
ambiguous nucleotides. In addition, the 12 nucleotides at the 3′ terminus of the reads
were discarded to remove a compositional nucleotide bias observed in a preliminary
screening, and residual sequencing adapters (ACACTCTTTCCCTACACGACGCTCTTCCGATCT,
GATCGGAAGAGCACACGTCTGAACTCCAGTCAC and GTGACTGGAGTTCAGACGTGTGCTCT
TCCGATCT) were detected and removed, setting the ‘mismatch_cost’, ‘gap_cost’,
‘minimum_internal_score’ and ‘minimum_score_at_ends’ to 3, 3, 10 and 4. In addition, poly(A)
stretches were removed because of the expected lack of match to the genome sequence. Similarly,
poly(G) sequence stretches were discarded as these are recognized as possible artefacts linked to the
lack of signal in the Illumina NextSeq sequencing chemistry.
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4.6. Differential Gene Expression Analysis
Trimmed reads from each library were mapped on the annotated coding regions of the reference
human genome (version Hg38) from the UCSC Genome Browser with the ‘RNA-seq analysis’ tool
included in the CLC Genomics Workbench. The parameters set to allow a non-ambiguous read mapping
were set as follows: mismatch cost = 2, insertion cost = 3, deletion cost = 3, length fraction = 0.98,
similarity fraction = 0.98. Tables containing raw read counts for each gene and each sequencing library
generated by the mapping process were grouped based on replicates and analysed with the CLC
Genomics Workbench via the ‘differential expression for RNA-seq’ tool, comparing each experimental
condition with the paired control at the same experimental time point. The generalized linear model
(GLM) used for this statistical analysis assumes that read counts follow a negative binomial distribution.
To identify significant differentially expressed genes (DEGs), only results with p-value ≤ 0.05 and fold
change ≥ |2| were considered as meaningful.
4.7. Ingenuity Pathway Analysis (IPA®)
Functional and pathway predictions were performed using Ingenuity Pathway Analysis (IPA®)
(Qiagen, Hilden, Germany), software based on a database (the Ingenuity knowledgebase) which
includes all the updated available information concerning gene regulatory networks in human.
Significant DEGs identified in the previous step of analysis with an emphasis on 1 h, the time point
with the most significant alterations, were used as input to identify the canonical pathways most
significantly affected by the lysozyme treatment and infer the upstream regulators and downstream
effects most likely to be involved in the process.
To identify the pathway specifically responsive to lysozyme, we took into account the most
significant DEGs to build a custom pathway based on the shortest relation sub-pathways between the
identified DEGs and other key genes predicted as likely to be significantly altered in a core IPA analysis.
4.8. Proteomic Analysis
Cells intended for proteomic analysis were collected 24 h after the end of each treatment,
centrifuged for 7 min (300× g) at 4 ◦C, washed with phosphate buffered saline (PBS) and centrifuged
again. The PBS was removed until approximately 50 µL of liquid remained. Cell pellets were snap
frozen in liquid N2 and stored at −80 ◦C until analysis.
Each sample was digested by filter aided sample preparation (FASP) [57] with minor modifications.
Dithiothreitol (DTT) was replaced by tris (2-carboxyethyl)phosphine (TCEP) as the reducing agent
and iodoacetamide by chloracetamide as the alkylating agent. A combined proteolytic digestion was
performed using endoproteinase Lys-C and trypsin. Peptides were desalted on C18 StageTips [58] and
dried down by vacuum centrifugation. Samples were then fractionated into six fractions by strong cation
exchange (SCX) chromatography on stage tips [59] and dried down again by vacuum centrifugation. For
LC MS/MS analysis, peptides were resuspended and then separated by reversed-phase chromatography
using a Dionex Ultimate 3000 RSLC nanoUPLC system on a home-made 75 µm ID × 50 cm C18
capillary column (Reprosil-Pur AQ 120 Å, 1.9 µm) in-line connected with an Orbitrap Q Exactive HF
Mass-Spectrometer (Thermo Fischer Scientific, Waltham, MA, USA). Database search was performed
using MaxQuant 1.6.0.1 [60] against the Human Uniprot database (Last Modified: 2017-05-23, 71567
canonical and isoform sequences) where the hen egg white lysozyme sequence (AFA52017.1, from
Uniprot, 2018-04-09) was added. Carbamidomethylation was set as fixed modification, whereas
oxidation (M), phosphorylation (S,T,Y), acetylation (protein N-term) and glutamine to pyroglutamate
were considered as variable modifications. A maximum of two missed cleavages were allowed for the
search and ‘match between runs’ option was selected. A minimum of two peptides were allowed for
protein identification and the false discovery rate (FDR) cut-off for both peptides and proteins was set
to 0.01. The MaxLFQ algorithm was used by MaxQuant for the label-free quantification (LFQ), with
the standard settings [61]. Perseus, the statistical validation tool embedded in MaxQuant, was used for
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further data validation [62]. Reverse proteins, contaminants and proteins only identified by sites were
filtered out. Biological replicates were grouped together and protein groups containing a minimum of
two LFQ values in at least one group were conserved. Missing values were imputed with random
numbers from a normal distribution (width = 0.4, down-shift = 1.8). Two-samples t-test coupled
with permutation-based correction (false discovery rate) was performed to identify the differentially
expressed proteins. Significant hits were determined by a volcano plot-based strategy, combining t-test
p-values with ratio information [63]. Significance curves in the volcano plot corresponded to a S0 value
of 0.5 and a FDR cut-off of 0.05. Further graphical displays were generated using homemade programs
written in R [64].
5. Conclusions
Herein, we bring new insights into the origin of the non-catalytic anti-inflammatory properties
of lysozyme. Because of the broad perspective of the RNA-sequencing analysis approach, this
study shows that the anti-inflammatory activity of lysozyme occurs owing to mechanisms of gene
regulation involving the TNF-α/IL-1β pathway modulation. Our findings, besides confirming the
alteration of proteins of the inflammatory pathway such as TNF-α and IL-1β, previously described
as affected by lysozyme treatment in scientific literature, enable their inclusion in a more expanded
and comprehensive picture, under the form of a functional network, where they are related to many
interactors. Furthermore, this approach demonstrates that such important, albeit transient, effects
of lysozyme can be achieved with the supplementation of relatively low concentrations of HEWL
for a short time of exposure. To the best of our knowledge, this is the first report to offer such
a broad overview of the anti-inflammatory effects of lysozyme at the gene expression level. The
novel data we report contributes to understanding the role of lysozyme at a molecular level in the
context of inflammatory processes, potentially allowing its potential in pharmacological applications
to be exploited.
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Abbreviations
AGEs Advanced Glycation End Products
CCL1 Chemokine Ligand 1
CCL3 Chemokine Ligand 3
CCL3L3 Chemokine Ligand 3-like 3
CCL7 Chemokine Ligand 7
CKMT2 Creatine Kinase Mitochondrial 2
DEGs Differentially Expressed Genes
DLG2 Discs Large MAGUK Scaffold Protein 2
DSS Dextran Sodium Sulphate
DTT Dithiothreitol
FASP Filter Aided Sample Preparation
FBS Foetal Bovine Serum
FDR False Discovery Rate
GI Gastrointestinal
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GLM Generalized Linear Model
HEWL Hen Egg-White Lysozyme
IER3 Immediate Early Response 3
IFNG Interferon Gamma
IL-1 Interleukin 1
IL-6 Interleukin 6
IPA Ingenuity Pathway Analysis
ISG15 Interferon-Stimulated Gene 15
JNK c-Jun N-terminal Kinase
LC-MS/MS Liquid Chromatography-tandem Mass Spectrometry
LFQ Label-Free Quantification
LPS Lipopolysaccharide
MAPK Mitogen Activated Protein Kinase
MMP-9 Matrix Metallopeptidase 9
NF-κB Nuclear Factor Kappa-light-chain-enhancer of activated B cells
PBS Phosphate Buffered Saline
PMA Phorbol-12-myristate 13-acetate
RAGE Receptor of AGE
SCX Strong Cation Exchange Chromatography
SNPs Single Nucleotide Polymorphisms
UC Ulcerative Colitis
TCEP Tris (2-carboxyethyl)phosphine
TMEM150C Transmembrane Protein 150C
TNF-α Tumour Necrosis factor alpha
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